VENUS MEDTECH-B(02500)Cardiovalve transseptal transcatheter mitral valve replacement system submitted CE MDR certification application

VENUS MEDTECH-B(02500) announced recently that the group has officially submitted all application materials for CE MDR certification to the European regulatory agency for the Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve system). The Cardiovalve system is a transcatheter intervention replacement product that can be used to treat both mitral regurgitation and tricuspid regurgitation. Compared to similar products, the Cardiovalve system's femoral vein access route significantly improves treatment safety, and its largest 55mm valve ring design is suitable for approximately 95% of patients. Additionally, its unique short valve frame design effectively reduces the risk of ventricular outflow obstruction. The Cardiovalve system is simple, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and releasing.